Production (Stage)
Allarity Therapeutics, Inc.
ALLR
$1.03
-$0.035-3.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -70.15% | 244.24% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -58.51% | 180.34% | |||
| Operating Income | 58.51% | -180.34% | |||
| Income Before Tax | 63.34% | 37.72% | |||
| Income Tax Expenses | -- | 100.00% | |||
| Earnings from Continuing Operations | 63.34% | 35.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 63.34% | 35.69% | |||
| EBIT | 58.51% | -180.34% | |||
| EBITDA | 58.65% | -180.84% | |||
| EPS Basic | 85.76% | 77.69% | |||
| Normalized Basic EPS | 85.76% | -19.77% | |||
| EPS Diluted | 85.76% | 77.69% | |||
| Normalized Diluted EPS | 85.76% | -19.77% | |||
| Average Basic Shares Outstanding | 157.36% | 174.86% | |||
| Average Diluted Shares Outstanding | 157.36% | 174.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||